{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T10:53:09Z","timestamp":1782298389700,"version":"3.54.5"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s11906-018-0807-9","type":"journal-article","created":{"date-parts":[[2018,2,24]],"date-time":"2018-02-24T04:29:31Z","timestamp":1519446571000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Sympathomimetic Toxidromes and Other Pharmacological Causes of Acute Hypertension"],"prefix":"10.1007","volume":"20","author":[{"given":"Andrew","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjana","family":"Dimovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Bisoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,24]]},"reference":[{"issue":"8","key":"807_CR1","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3109\/15563650.2011.615318","volume":"49","author":"SL Hill","year":"2011","unstructured":"\u2022\u2022 Hill SL, Thomas SH. Clinical toxicology of newer recreational drugs. Clin Toxicol (Phila). 2011;49(8):705\u201319. Recent extensive review of available information on synthetic \u201cdesigner\u201d drugs utilizing peer-reviewed literature to date as well as media and drug user forums, books, and government publications. https:\/\/doi.org\/10.3109\/15563650.2011.615318.","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"807_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1196\/annals.1316.024","volume":"1025","author":"MH Baumann","year":"2004","unstructured":"Baumann MH, et al. Effects of \u201cLegal X\u201d piperazine analogs on dopamine and serotonin release in rat brain. Ann N Y Acad Sci. 2004;1025(1):189\u201397. https:\/\/doi.org\/10.1196\/annals.1316.024.","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"807_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3109\/15563650.2011.572076","volume":"49","author":"LJ Schep","year":"2011","unstructured":"Schep LJ, et al. The clinical toxicology of the designer \u201cparty pills\u201d benzylpiperazine and trifluoromethylphenylpiperazine. Clin Toxicol (Phila). 2011;49(3):131\u201341. https:\/\/doi.org\/10.3109\/15563650.2011.572076.","journal-title":"Clin Toxicol (Phila)"},{"key":"807_CR4","unstructured":"Cho, A.K. and D.S. Segal, Amphetamine and its analogs : psychopharmacology, toxicology, and abuse. 1994, San Diego: Academic Press. xxi, 503 p."},{"issue":"7","key":"807_CR5","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/sj.bjp.0705722","volume":"141","author":"CA Villalobos","year":"2004","unstructured":"Villalobos CA, et al. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes. Br J Pharmacol. 2004;141(7):1167\u201374. https:\/\/doi.org\/10.1038\/sj.bjp.0705722.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"807_CR6","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/sj.bjp.0704747","volume":"136","author":"C Acuna-Castillo","year":"2002","unstructured":"Acuna-Castillo C, et al. Differences in potency and efficacy of a series of phenylisopropylamine\/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors. Br J Pharmacol. 2002;136(4):510\u20139. https:\/\/doi.org\/10.1038\/sj.bjp.0704747.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"807_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/BF03178273","volume":"5","author":"DM Wood","year":"2009","unstructured":"Wood DM, et al. Delayed onset of seizures and toxicity associated with recreational use of Bromo-dragonFLY. J Med Toxicol. 2009;5(4):226\u20139. https:\/\/doi.org\/10.1007\/BF03178273.","journal-title":"J Med Toxicol"},{"issue":"4","key":"807_CR8","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1021\/jm050797a","volume":"49","author":"PC Meltzer","year":"2006","unstructured":"Meltzer PC, et al. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006;49(4):1420\u201332. https:\/\/doi.org\/10.1021\/jm050797a.","journal-title":"J Med Chem"},{"issue":"11","key":"807_CR9","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1001\/jama.1983.03330350053028","volume":"249","author":"JS Bowen","year":"1983","unstructured":"Bowen JS, et al. Diffuse vascular spasm associated with 4-bromo-2,5-dimethoxyamphetamine ingestion. JAMA. 1983;249(11):1477\u20139. https:\/\/doi.org\/10.1001\/jama.1983.03330350053028.","journal-title":"JAMA"},{"issue":"1","key":"807_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.forsciint.2005.04.022","volume":"153","author":"M Balikova","year":"2005","unstructured":"Balikova M. Nonfatal and fatal DOB (2,5-dimethoxy-4-bromoamphetamine) overdose. Forensic Sci Int. 2005;153(1):85\u201391. https:\/\/doi.org\/10.1016\/j.forsciint.2005.04.022.","journal-title":"Forensic Sci Int"},{"issue":"1\u20133","key":"807_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.forsciint.2008.11.001","volume":"183","author":"MF Andreasen","year":"2009","unstructured":"Andreasen MF, et al. A fatal poisoning involving Bromo-dragonfly. Forensic Sci Int. 2009;183(1\u20133):91\u20136. https:\/\/doi.org\/10.1016\/j.forsciint.2008.11.001.","journal-title":"Forensic Sci Int"},{"issue":"16","key":"807_CR12","first-page":"1199","volume":"105","author":"K Thorlacius","year":"2008","unstructured":"Thorlacius K, Borna C, Personne M. Bromo-dragon fly\u2014life-threatening drug. Can cause tissue necrosis as demonstrated by the first described case. Lakartidningen. 2008;105(16):1199\u2013200.","journal-title":"Lakartidningen"},{"issue":"7","key":"807_CR13","doi-asserted-by":"crossref","first-page":"426","DOI":"10.5694\/j.1326-5377.2008.tb01695.x","volume":"188","author":"PG Lamberth","year":"2008","unstructured":"Lamberth PG, Ding GK, Nurmi LA. Fatal paramethoxy-amphetamine (PMA) poisoning in the Australian Capital Territory. Med J Aust. 2008;188(7):426.","journal-title":"Med J Aust"},{"issue":"3","key":"807_CR14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.tox.2006.10.024","volume":"229","author":"H Carmo","year":"2007","unstructured":"Carmo H, et al. CYP2D6 increases toxicity of the designer drug 4-methylthioamphetamine (4-MTA). Toxicology. 2007;229(3):236\u201344. https:\/\/doi.org\/10.1016\/j.tox.2006.10.024.","journal-title":"Toxicology"},{"issue":"4","key":"807_CR15","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.annemergmed.2012.11.021","volume":"61","author":"M Levine","year":"2013","unstructured":"Levine M, Levitan R, Skolnik A. Compartment syndrome after \u201cbath salts\u201d use: a case series. Ann Emerg Med. 2013;61(4):480\u20133. https:\/\/doi.org\/10.1016\/j.annemergmed.2012.11.021.","journal-title":"Ann Emerg Med"},{"issue":"2","key":"807_CR16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/jat\/32.2.172","volume":"32","author":"S Elliott","year":"2008","unstructured":"Elliott S, Smith C. Investigation of the first deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP. J Anal Toxicol. 2008;32(2):172\u20137. https:\/\/doi.org\/10.1093\/jat\/32.2.172.","journal-title":"J Anal Toxicol"},{"issue":"3","key":"807_CR17","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3109\/15563651003592948","volume":"48","author":"P Gee","year":"2010","unstructured":"Gee P, Jerram T, Bowie D. Multiorgan failure from 1-benzylpiperazine ingestion\u2014legal high or lethal high? Clin Toxicol (Phila). 2010;48(3):230\u20133. https:\/\/doi.org\/10.3109\/15563651003592948.","journal-title":"Clin Toxicol (Phila)"},{"issue":"1227","key":"807_CR18","first-page":"U1784","volume":"118","author":"P Gee","year":"2005","unstructured":"Gee P, et al. Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand. N Z Med J. 2005;118(1227):U1784.","journal-title":"N Z Med J"},{"issue":"4","key":"807_CR19","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1080\/j.1440-1665.2004.02137.x","volume":"12","author":"H Austin","year":"2004","unstructured":"Austin H, Monasterio E. Acute psychosis following ingestion of \u201cRapture\u201d. Australas Psychiatry. 2004;12(4):406\u20138. https:\/\/doi.org\/10.1080\/j.1440-1665.2004.02137.x.","journal-title":"Australas Psychiatry"},{"issue":"9","key":"807_CR20","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1177\/0269881109102608","volume":"24","author":"I Thompson","year":"2010","unstructured":"Thompson I, et al. Randomised double-blind, placebo-controlled trial of the effects of the \u201cparty pills\u201d BZP\/TFMPP alone and in combination with alcohol. J Psychopharmacol. 2010;24(9):1299\u2013308. https:\/\/doi.org\/10.1177\/0269881109102608.","journal-title":"J Psychopharmacol"},{"issue":"8","key":"807_CR21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3109\/15563650.2012.716158","volume":"50","author":"DM Wood","year":"2012","unstructured":"Wood DM, Dargan PI. Use and acute toxicity associated with the novel psychoactive substances diphenylprolinol (D2PM) and desoxypipradrol (2-DPMP). Clin Toxicol (Phila). 2012;50(8):727\u201332. https:\/\/doi.org\/10.3109\/15563650.2012.716158.","journal-title":"Clin Toxicol (Phila)"},{"issue":"2","key":"807_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3109\/15563650.2011.647992","volume":"50","author":"DB Murray","year":"2012","unstructured":"Murray DB, et al. \u2018Ivory wave\u2019 toxicity in recreational drug users; integration of clinical and poisons information services to manage legal high poisoning. Clin Toxicol (Phila). 2012;50(2):108\u201313. https:\/\/doi.org\/10.3109\/15563650.2011.647992.","journal-title":"Clin Toxicol (Phila)"},{"issue":"11","key":"807_CR23","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1097\/00003246-198611000-00011","volume":"14","author":"J Rosenberg","year":"1986","unstructured":"Rosenberg J, et al. Hyperthermia associated with drug intoxication. Crit Care Med. 1986;14(11):964\u20139. https:\/\/doi.org\/10.1097\/00003246-198611000-00011.","journal-title":"Crit Care Med"},{"issue":"6","key":"807_CR24","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.mcna.2005.06.002","volume":"89","author":"DE Rusyniak","year":"2005","unstructured":"\u2022 Rusyniak DE, Sprague JE. Toxin-induced hyperthermic syndromes. Med Clin North Am. 2005;89(6):1277\u201396. Review of toxin-induced hyperthermia syndromes related to appropriate diagnosis and treatment of these conditions. https:\/\/doi.org\/10.1016\/j.mcna.2005.06.002.","journal-title":"Med Clin North Am"},{"issue":"2","key":"807_CR25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.annemergmed.2007.02.022","volume":"50","author":"P Levy","year":"2007","unstructured":"Levy P, et al. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. Ann Emerg Med. 2007;50(2):144\u201352. https:\/\/doi.org\/10.1016\/j.annemergmed.2007.02.022.","journal-title":"Ann Emerg Med"},{"issue":"3","key":"807_CR26","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/00000542-199609000-00026","volume":"85","author":"JC Eisenach","year":"1996","unstructured":"Eisenach JC, De Kock M, Klimscha W. Alpha(2)-adrenergic agonists for regional anesthesia. A clinical review of clonidine (1984-1995). Anesthesiology. 1996;85(3):655\u201374. https:\/\/doi.org\/10.1097\/00000542-199609000-00026.","journal-title":"Anesthesiology"},{"issue":"4","key":"807_CR27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jemermed.2003.04.002","volume":"25","author":"J Simic","year":"2003","unstructured":"Simic J, et al. Acute myocardial infarction as a complication of clonidine withdrawal. J Emerg Med. 2003;25(4):399\u2013402. https:\/\/doi.org\/10.1016\/j.jemermed.2003.04.002.","journal-title":"J Emerg Med"},{"issue":"5 Pt 2","key":"807_CR28","first-page":"II71","volume":"6","author":"JL Reid","year":"1984","unstructured":"Reid JL, Campbell BC, Hamilton CA. Withdrawal reactions following cessation of central alpha-adrenergic receptor agonists. Hypertension. 1984;6(5 Pt 2):II71\u20135.","journal-title":"Hypertension"},{"issue":"2","key":"807_CR29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/BF02291233","volume":"6","author":"NJ Sarlis","year":"1996","unstructured":"Sarlis NJ, et al. Hyperadrenergic state following acute withdrawal from clonidine used at supratherapeutic doses. Clin Auton Res. 1996;6(2):115\u20137. https:\/\/doi.org\/10.1007\/BF02291233.","journal-title":"Clin Auton Res"},{"issue":"12","key":"807_CR30","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1001\/archpsyc.1986.01800120054011","volume":"43","author":"JF Leckman","year":"1986","unstructured":"Leckman JF, et al. Rebound phenomena in Tourette\u2019s syndrome after abrupt withdrawal of clonidine. Behavioral, cardiovascular, and neurochemical effects. Arch Gen Psychiatry. 1986;43(12):1168\u201376. https:\/\/doi.org\/10.1001\/archpsyc.1986.01800120054011.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"807_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1213\/00000539-199102000-00023","volume":"72","author":"KH Berge","year":"1991","unstructured":"Berge KH, Lanier WL. Myocardial infarction accompanying acute clonidine withdrawal in a patient without a history of ischemic coronary artery disease. Anesth Analg. 1991;72(2):259\u201361. https:\/\/doi.org\/10.1213\/00000539-199102000-00023.","journal-title":"Anesth Analg"},{"issue":"786","key":"807_CR32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1136\/pgmj.67.786.403","volume":"67","author":"P Jain","year":"1991","unstructured":"Jain P, Misra A. Non-sustained ventricular tachycardia following clonidine withdrawal. Postgrad Med J. 1991;67(786):403\u20134. https:\/\/doi.org\/10.1136\/pgmj.67.786.403.","journal-title":"Postgrad Med J"},{"issue":"7","key":"807_CR33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4103\/1947-2714.115767","volume":"5","author":"V Abrich","year":"2013","unstructured":"Abrich V, Martin P, Hennick M. Vertebral artery dissection and lateral medullary stroke associated with neck trauma and clonidine withdrawal. N Am J Med Sci. 2013;5(7):443\u20134. https:\/\/doi.org\/10.4103\/1947-2714.115767.","journal-title":"N Am J Med Sci"},{"key":"807_CR34","doi-asserted-by":"crossref","unstructured":"Shaw M, Matsa R. Clonidine withdrawal induced sympathetic surge. BMJ Case Rep. 2015;2015","DOI":"10.1136\/bcr-2015-210325"},{"issue":"3","key":"807_CR35","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/00000542-199603000-00031","volume":"84","author":"D Fitzgibbon","year":"1996","unstructured":"Fitzgibbon D, et al. Rebound hypertension and withdrawal associated with discontinuation of an infusion of epidural clonidine. Anesthesiology. 1996;84(3):729\u201331. https:\/\/doi.org\/10.1097\/00000542-199603000-00031.","journal-title":"Anesthesiology"},{"issue":"1","key":"807_CR36","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s13181-015-0505-9","volume":"12","author":"HM Lee","year":"2016","unstructured":"Lee HM, Ruggoo V, Graudins A. Intrathecal clonidine pump failure causing acute withdrawal syndrome with \u2018Stress-Induced\u2019 cardiomyopathy. J Med Toxicol. 2016;12(1):134\u20138. https:\/\/doi.org\/10.1007\/s13181-015-0505-9.","journal-title":"J Med Toxicol"},{"issue":"6","key":"807_CR37","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/PCC.0b013e318253c7f1","volume":"13","author":"P Gupta","year":"2012","unstructured":"Gupta P, et al. Safety and efficacy of prolonged dexmedetomidine use in critically ill children with heart disease. Pediatr Crit Care Med. 2012;13(6):660\u20136. https:\/\/doi.org\/10.1097\/PCC.0b013e318253c7f1.","journal-title":"Pediatr Crit Care Med"},{"issue":"12","key":"807_CR38","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1007\/s00134-004-2417-z","volume":"30","author":"Y Shehabi","year":"2004","unstructured":"\u2022 Shehabi Y, et al. Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive Care Med. 2004;30(12):2188\u201396. Helpful review of alpha\n                              \n                      2\n                     agonist withdrawal in the form of an editorial, discussing the possibility of tolerance and withdrawal from an ICU physician perspective. https:\/\/doi.org\/10.1007\/s00134-004-2417-z.","journal-title":"Intensive Care Med"},{"issue":"1","key":"807_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/0960327112454896","volume":"32","author":"A Kukoyi","year":"2013","unstructured":"Kukoyi A, et al. Two cases of acute dexmedetomidine withdrawal syndrome following prolonged infusion in the intensive care unit: report of cases and review of the literature. Hum Exp Toxicol. 2013;32(1):107\u201310. https:\/\/doi.org\/10.1177\/0960327112454896.","journal-title":"Hum Exp Toxicol"},{"issue":"1","key":"807_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1460-9592.2007.02377.x","volume":"18","author":"MD Weber","year":"2008","unstructured":"Weber MD, Thammasitboon S, Rosen DA. Acute discontinuation syndrome from dexmedetomidine after protracted use in a pediatric patient. Paediatr Anaesth. 2008;18(1):87\u20138. https:\/\/doi.org\/10.1111\/j.1460-9592.2007.02377.x.","journal-title":"Paediatr Anaesth"},{"issue":"3","key":"807_CR41","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1001\/archinte.1986.00360150236029","volume":"146","author":"MC Houston","year":"1986","unstructured":"Houston MC. Treatment of hypertensive emergencies and urgencies with oral clonidine loading and titration. A review. Arch Intern Med. 1986;146(3):586\u20139. https:\/\/doi.org\/10.1001\/archinte.1986.00360150236029.","journal-title":"Arch Intern Med"},{"issue":"3","key":"807_CR42","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/phar.1559","volume":"35","author":"DJ Gagnon","year":"2015","unstructured":"Gagnon DJ, et al. Transition from dexmedetomidine to enteral clonidine for ICU sedation: an observational pilot study. Pharmacotherapy. 2015;35(3):251\u20139. https:\/\/doi.org\/10.1002\/phar.1559.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"807_CR43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5863\/1551-6776-20.1.45","volume":"20","author":"AB Lardieri","year":"2015","unstructured":"Lardieri AB, et al. Effects of clonidine on withdrawal from long-term dexmedetomidine in the pediatric patient. J Pediatr Pharmacol Ther. 2015;20(1):45\u201353. https:\/\/doi.org\/10.5863\/1551-6776-20.1.45.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"1","key":"807_CR44","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/PCC.0b013e3181ae49af","volume":"11","author":"JD Tobias","year":"2010","unstructured":"Tobias JD. Dexmedetomidine: are tolerance and withdrawal going to be an issue with long-term infusions? Pediatr Crit Care Med. 2010;11(1):158\u201360. https:\/\/doi.org\/10.1097\/PCC.0b013e3181ae49af.","journal-title":"Pediatr Crit Care Med"},{"issue":"3","key":"807_CR45","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/1751143716638374","volume":"17","author":"E Bowcock","year":"2016","unstructured":"Bowcock E, Morris I, Lane A. Dexmedetomidine for acute clonidine withdrawal following intrathecal pump removal: a drug beginning to find its expanding niche. J Intensive Care Soc. 2016;17(3):271\u20132. https:\/\/doi.org\/10.1177\/1751143716638374.","journal-title":"J Intensive Care Soc"},{"issue":"1","key":"807_CR46","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3109\/17482941.2016.1174273","volume":"18","author":"SO Awuor","year":"2016","unstructured":"Awuor SO, et al. Intrathecal baclofen withdrawal: a rare cause of reversible cardiomyopathy. Acute Card Care. 2016;18(1):13\u20137. https:\/\/doi.org\/10.3109\/17482941.2016.1174273.","journal-title":"Acute Card Care"},{"key":"807_CR47","doi-asserted-by":"publisher","unstructured":"Cardoso AL, Quintaneiro C, Seabra H, Teixeira C. Cardiac arrest due to baclofen withdrawal syndrome. BMJ Case Rep. 2014. https:\/\/doi.org\/10.1136\/bcr-2014-204322.","DOI":"10.1136\/bcr-2014-204322"},{"issue":"2","key":"807_CR48","first-page":"81","volume":"22","author":"G D\u2019Aleo","year":"2007","unstructured":"D\u2019Aleo G, et al. Hallucinations after abrupt withdrawal of oral and intrathecal baclofen. Funct Neurol. 2007;22(2):81\u20138.","journal-title":"Funct Neurol"},{"issue":"4","key":"807_CR49","doi-asserted-by":"crossref","first-page":"E633","DOI":"10.36076\/ppj.2015\/18\/E","volume":"18","author":"I Stetkarova","year":"2015","unstructured":"Stetkarova I, et al. Intrathecal baclofen in spinal spasticity: frequency and severity of withdrawal syndrome. Pain Physician. 2015;18(4):E633\u201341.","journal-title":"Pain Physician"},{"issue":"2","key":"807_CR50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/sc.2011.112","volume":"50","author":"SV Watve","year":"2012","unstructured":"\u2022\u2022 Watve SV, et al. Management of acute overdose or withdrawal state in intrathecal baclofen therapy. Spinal Cord. 2012;50(2):107\u201311. Recent review of studies relevant to the management of patients with intrathecal baclofen overdose and withdrawal. https:\/\/doi.org\/10.1038\/sc.2011.112.","journal-title":"Spinal Cord"},{"issue":"3","key":"807_CR51","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.yebeh.2011.04.052","volume":"21","author":"N Specchio","year":"2011","unstructured":"Specchio N, et al. Prolonged episode of dystonia and dyskinesia resembling status epilepticus following acute intrathecal baclofen withdrawal. Epilepsy Behav. 2011;21(3):321\u20133. https:\/\/doi.org\/10.1016\/j.yebeh.2011.04.052.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"807_CR52","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0736-4679(03)00039-8","volume":"24","author":"LW Kao","year":"2003","unstructured":"Kao LW, et al. Intrathecal baclofen withdrawal mimicking sepsis. J Emerg Med. 2003;24(4):423\u20137. https:\/\/doi.org\/10.1016\/S0736-4679(03)00039-8.","journal-title":"J Emerg Med"},{"issue":"2","key":"807_CR53","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s12028-014-0083-8","volume":"22","author":"S Morr","year":"2015","unstructured":"Morr S, et al. Dexmedetomidine for acute baclofen withdrawal. Neurocrit Care. 2015;22(2):288\u201392. https:\/\/doi.org\/10.1007\/s12028-014-0083-8.","journal-title":"Neurocrit Care"},{"issue":"1","key":"807_CR54","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1081\/CLT-120018277","volume":"41","author":"MI Greenberg","year":"2003","unstructured":"Greenberg MI, Hendrickson RG. Baclofen withdrawal following removal of an intrathecal baclofen pump despite oral baclofen replacement. J Toxicol Clin Toxicol. 2003;41(1):83\u20135. https:\/\/doi.org\/10.1081\/CLT-120018277.","journal-title":"J Toxicol Clin Toxicol"},{"issue":"12","key":"807_CR55","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.4065\/mcp.2011.0338","volume":"86","author":"JB Finkel","year":"2011","unstructured":"\u2022 Finkel JB, Marhefka GD. Rethinking cocaine-associated chest pain and acute coronary syndromes. Mayo Clin Proc. 2011;86(12):1198\u2013207. Review of cocaine-associated chest pain and beta-blocker use from a unique author\u2019s perspective. https:\/\/doi.org\/10.4065\/mcp.2011.0338.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"807_CR56","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.annemergmed.2007.08.020","volume":"51","author":"K Freeman","year":"2008","unstructured":"\u2022 Freeman K, Feldman JA. Cocaine, myocardial infarction, and beta-blockers: time to rethink the equation? Ann Emerg Med. 2008;51(2):130\u20134. Review of cocaine-associated chest pain and beta-blocker use from a unique author\u2019s perspective. https:\/\/doi.org\/10.1016\/j.annemergmed.2007.08.020.","journal-title":"Ann Emerg Med"},{"issue":"4","key":"807_CR57","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1097\/00003246-199904000-00012","volume":"27","author":"JB Leikin","year":"1999","unstructured":"\u2022 Leikin JB. Cocaine and beta-adrenergic blockers: a remarriage after a decade-long divorce? Crit Care Med. 1999;27(4):688\u20139. Review of cocaine-associated chest pain and beta-blocker use from a unique author\u2019s perspective. https:\/\/doi.org\/10.1097\/00003246-199904000-00012.","journal-title":"Crit Care Med"},{"key":"807_CR58","doi-asserted-by":"publisher","unstructured":"\u2022 Mariani PJ. Beta-blockers following cocaine use: a reappraisal. Ann Emerg Med. 2008;52(1):89; author reply 89\u201390. Review of cocaine-associated chest pain and beta-blocker use from a unique author\u2019s perspective. https:\/\/doi.org\/10.1016\/j.annemergmed.2007.11.048.","DOI":"10.1016\/j.annemergmed.2007.11.048"},{"issue":"12","key":"807_CR59","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1345\/aph.1H643","volume":"41","author":"RL Page II","year":"2007","unstructured":"\u2022 Page RL II, Utz KJ, Wolfel EE. Should beta-blockers be used in the treatment of cocaine-associated acute coronary syndrome? Ann Pharmacother. 2007;41(12):2008\u201313. Review of cocaine-associated chest pain and beta-blocker use from a unique author\u2019s perspective. https:\/\/doi.org\/10.1345\/aph.1H643.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"807_CR60","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1177\/1074248416681644","volume":"22","author":"JR Richards","year":"2017","unstructured":"\u2022 Richards JR, et al. Beta-blockers, cocaine, and the unopposed alpha-stimulation phenomenon. J Cardiovasc Pharmacol Ther. 2017;22(3):239\u201349. Review of cocaine-associated chest pain and beta-blocker use from a unique author\u2019s perspective. https:\/\/doi.org\/10.1177\/1074248416681644.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"12","key":"807_CR61","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/phar.1486","volume":"34","author":"JW Schurr","year":"2014","unstructured":"\u2022 Schurr JW, Gitman B, Belchikov Y. Controversial therapeutics: the beta-adrenergic antagonist and cocaine-associated cardiovascular complications dilemma. Pharmacotherapy. 2014;34(12):1269\u201381. Review of cocaine-associated chest pain and beta-blocker use from a unique author\u2019s perspective. https:\/\/doi.org\/10.1002\/phar.1486.","journal-title":"Pharmacotherapy"},{"issue":"5","key":"807_CR62","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3109\/15563650.2016.1142090","volume":"54","author":"JR Richards","year":"2016","unstructured":"\u2022\u2022 Richards JR, et al. Treatment of cocaine cardiovascular toxicity: a systematic review. Clin Toxicol (Phila). 2016;54(5):345\u201364. Most extensive and recent review on available evidence regarding the treatment of cocaine-related cardiovascular toxicity to date. https:\/\/doi.org\/10.3109\/15563650.2016.1142090.","journal-title":"Clin Toxicol (Phila)"},{"issue":"8","key":"807_CR63","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1136\/emj.2009.079905","volume":"27","author":"CM Hysek","year":"2010","unstructured":"Hysek CM, Vollenweider FX, Liechti ME. Effects of a beta-blocker on the cardiovascular response to MDMA (Ecstasy). Emerg Med J. 2010;27(8):586\u20139. https:\/\/doi.org\/10.1136\/emj.2009.079905.","journal-title":"Emerg Med J"},{"issue":"1","key":"807_CR64","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3109\/15563659208994450","volume":"30","author":"KK Burkhart","year":"1992","unstructured":"Burkhart KK. Intravenous propranolol reverses hypertension after sympathomimetic overdose: two case reports. J Toxicol Clin Toxicol. 1992;30(1):109\u201314. https:\/\/doi.org\/10.3109\/15563659208994450.","journal-title":"J Toxicol Clin Toxicol"},{"issue":"1","key":"807_CR65","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/15563657909030114","volume":"14","author":"RT Rappolt Sr","year":"1979","unstructured":"Rappolt RT Sr, et al. Treatment plan for acute and chronic adrenergic poisoning crisis utilizing sympatholytic effects of the B1-B2 receptor site blocker propranolol (Inderal) in concert with diazepam and urine acidification. Clin Toxicol. 1979;14(1):55\u201369. https:\/\/doi.org\/10.3109\/15563657909030114.","journal-title":"Clin Toxicol"},{"issue":"11","key":"807_CR66","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.1016\/S0828-282X(08)70200-9","volume":"24","author":"S Akay","year":"2008","unstructured":"Akay S, Ozdemir M. Acute coronary syndrome presenting after pseudoephedrine use and regression with beta-blocker therapy. Can J Cardiol. 2008;24(11):e86\u20138. https:\/\/doi.org\/10.1016\/S0828-282X(08)70200-9.","journal-title":"Can J Cardiol"},{"issue":"2","key":"807_CR67","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.annemergmed.2007.04.015","volume":"51","author":"PB Dattilo","year":"2008","unstructured":"\u2022 Dattilo PB, Hailpern SM, Fearon K, Sohal D, Nordin C. Beta-blockers are associated with reduced risk of myocardial infarction after cocaine use. Ann Emerg Med. 2008;51(2):117\u201325. Retrospective cohort study demonstrating an association of reduced risk for MI in patients with positive drug screens for cocaine who received beta blockade during admission. https:\/\/doi.org\/10.1016\/j.annemergmed.2007.04.015.","journal-title":"Ann Emerg Med"},{"issue":"1","key":"807_CR68","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1177\/1074248409358409","volume":"15","author":"MH Hoskins","year":"2010","unstructured":"Hoskins MH, et al. Effects of labetalol on hemodynamic parameters and soluble biomarkers of inflammation in acute coronary syndrome in patients with active cocaine use. J Cardiovasc Pharmacol Ther. 2010;15(1):47\u201352. https:\/\/doi.org\/10.1177\/1074248409358409.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"3","key":"807_CR69","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ajem.2012.09.027","volume":"31","author":"M Ibrahim","year":"2013","unstructured":"\u2022 Ibrahim M, Maselli DJ, Hasan R, Hamilton A. Safety of beta-blockers in the acute management of cocaine-associated chest pain. Am J Emerg Med. 2013;31(3):613\u20136. Retrospective chart review of patients with cocaine-associated chest pain showing no increase in troponin in patients who received beta blockers during admission compared to those who did not. https:\/\/doi.org\/10.1016\/j.ajem.2012.09.027.","journal-title":"Am J Emerg Med"},{"key":"807_CR70","doi-asserted-by":"crossref","unstructured":"\u2022 Rangel C, et al. Beta-blockers for chest pain associated with recent cocaine use. Arch Intern Med. 2010;(10):170, 874\u20139. Retrospective review of patients with positive urine drug screen for coccaine comparing those who received a beta-blocker with those who did not, showing no association with adverse event.","DOI":"10.1001\/archinternmed.2010.115"},{"issue":"1","key":"807_CR71","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1053\/ajem.2003.50010","volume":"21","author":"T Honderick","year":"2003","unstructured":"\u2022\u2022 Honderick T, Williams D, Seaberg D, Wears R. A prospective, randomized, controlled trial of benzodiazepines and nitroglycerine or nitroglycerine alone in the treatment of cocaine-associated acute coronary syndromes. Am J Emerg Med. 2003;21(1):39\u201342. Basis of the evidence for benzodiazepine use in cocaine-associated chest pain. Randomized controlled trial showing improvement in pain in patients who received lorazepam + nitroglycerine vs nitroglycerin alone. https:\/\/doi.org\/10.1053\/ajem.2003.50010.","journal-title":"Am J Emerg Med"},{"issue":"8","key":"807_CR72","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/j.1553-2712.2000.tb02065.x","volume":"7","author":"BM Baumann","year":"2000","unstructured":"\u2022 Baumann BM, Perrone J, Hornig SE, Shofer FS, Hollander JE. Randomized, double-blind, placebo-controlled trial of diazepam, nitroglycerin, or both for treatment of patients with potential cocaine-associated acute coronary syndromes. Acad Emerg Med. 2000;7(8):878\u201385. Randomized controlled trial showing no difference in diazepam + nitroglycerin versus nitroglycerin alone in the resolution chest pain or changes in stroke index. https:\/\/doi.org\/10.1111\/j.1553-2712.2000.tb02065.x.","journal-title":"Acad Emerg Med"},{"issue":"8","key":"807_CR73","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJM199602223340803","volume":"334","author":"J Hinchey","year":"1996","unstructured":"Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494\u2013500. https:\/\/doi.org\/10.1056\/NEJM199602223340803.","journal-title":"N Engl J Med"},{"issue":"5","key":"807_CR74","doi-asserted-by":"publisher","first-page":"427","DOI":"10.4065\/mcp.2009.0590","volume":"85","author":"JE Fugate","year":"2010","unstructured":"Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85(5):427\u201332. https:\/\/doi.org\/10.4065\/mcp.2009.0590.","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"807_CR75","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S1474-4422(15)00111-8","volume":"14","author":"JE Fugate","year":"2015","unstructured":"\u2022\u2022 Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914\u201325. Most recent and comprehensive review regarding etiology, diagnosis, and treatment of PRES to date. https:\/\/doi.org\/10.1016\/S1474-4422(15)00111-8.","journal-title":"Lancet Neurol"},{"issue":"9","key":"807_CR76","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.autrev.2015.05.006","volume":"14","author":"G Granata","year":"2015","unstructured":"Granata G, et al. Posterior reversible encephalopathy syndrome\u2014insight into pathogenesis, clinical variants and treatment approaches. Autoimmun Rev. 2015;14(9):830\u20136. https:\/\/doi.org\/10.1016\/j.autrev.2015.05.006.","journal-title":"Autoimmun Rev"},{"issue":"12","key":"807_CR77","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1007\/s00296-017-3843-x","volume":"37","author":"T Zekic","year":"2017","unstructured":"Zekic T, et al. The multifactorial origin of posterior reversible encephalopathy syndrome in cyclophosphamide-treated lupus patients. Rheumatol Int. 2017;37(12):2105\u201314. https:\/\/doi.org\/10.1007\/s00296-017-3843-x.","journal-title":"Rheumatol Int"},{"issue":"6","key":"807_CR78","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jclinane.2010.12.017","volume":"23","author":"R Gharabawy","year":"2011","unstructured":"Gharabawy R, et al. Epinephrine-induced posterior reversible encephalopathy syndrome: a case report. J Clin Anesth. 2011;23(6):505\u20137. https:\/\/doi.org\/10.1016\/j.jclinane.2010.12.017.","journal-title":"J Clin Anesth"},{"issue":"1","key":"807_CR79","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1186\/1752-1947-8-442","volume":"8","author":"JL Jayaweera","year":"2014","unstructured":"Jayaweera JL, et al. Cyclophosphamide-induced posterior reversible encephalopathy syndrome (PRES): a case report. J Med Case Rep. 2014;8(1):442. https:\/\/doi.org\/10.1186\/1752-1947-8-442.","journal-title":"J Med Case Rep"},{"key":"807_CR80","doi-asserted-by":"crossref","unstructured":"Omer TA, Doherty C. Posterior reversible encephalopathy syndrome (PRES) complicating the \u2018legal high\u2019 mephedrone. BMJ Case Rep. 2011;2011","DOI":"10.1136\/bcr.02.2011.3904"},{"issue":"14","key":"807_CR81","doi-asserted-by":"publisher","first-page":"e3173","DOI":"10.1097\/MD.0000000000003173","volume":"95","author":"T Song","year":"2016","unstructured":"\u2022 Song T, Rao Z, Tan Q, Qiu Y, Liu J, Huang Z, et al. Calcineurin inhibitors associated posterior reversible encephalopathy syndrome in solid organ transplantation: report of 2 cases and literature review. Medicine (Baltimore). 2016;95(14):e3173. Good recent review and report of current understanding regarding the connection between PRES and 2 of its most commonly associated agents. https:\/\/doi.org\/10.1097\/MD.0000000000003173.","journal-title":"Medicine (Baltimore)"},{"issue":"21","key":"807_CR82","doi-asserted-by":"publisher","first-page":"6691","DOI":"10.3748\/wjg.v20.i21.6691","volume":"20","author":"W Wang","year":"2014","unstructured":"Wang W, Zhao LR, Lin XQ, Feng F. Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancer. World J Gastroenterol. 2014;20(21):6691\u20137. https:\/\/doi.org\/10.3748\/wjg.v20.i21.6691.","journal-title":"World J Gastroenterol"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11906-018-0807-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-018-0807-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-018-0807-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:10:29Z","timestamp":1744175429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11906-018-0807-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["807"],"URL":"https:\/\/doi.org\/10.1007\/s11906-018-0807-9","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"24 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no conflicts of interest relevant to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"8"}}